Analysts unveils stock market game plans after Fed-driven tumble
Market veterans break down the story behind the market's recent tumble.
Market veterans break down the story behind the market's recent tumble.
Carvana stock could rocket back toward three-year highs, if past is precedent
Cintas shares tumbled Thursday as the provider of uniforms and other business supplies reported a decline in direct sales of its uniforms and warned about pricing.
The year ahead promises to be interesting for investors. We explore what experts say about the competing dynamics in 2025 and their impact on different areas of the stock market.
New research shows that the resale sector is accelerating fast, and has overtaken sales in the broader apparel, accessories and footwear categories.
Soho House’s billionaire chairman has revived efforts to take the private members’ club off the US stock market, backing a near $1.8bn (£1.4bn) buyout bid.
On Thursday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR), a disorder that causes pain in the lower back and hip that radiates down the back of the thigh into the leg. The study met its primary endpoint with a statistically significant and clinically meaningful reduction in pain on the numeric pain rating scale (NPRS). The suzetrigine arm showed a statistically significant and clinically mean
Micron Technology shares tanked Thursday after the chipmaker warned about near-term demand issues.
Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.
Major U.S. indexes rallied at midday Thursday, rebounding from Wednesday's selloff as a report showed the U.S. economy expanded more than anticipated in the third quarter.